Smith+Nebhew has entered into an exclusive U.S. distribution agreement with RMR Ortho, a subsidiary of The RMR Group Inc., for its A'TOMIC™ Nitinol Fixation System. The dynamic‑compression device, designed for fracture, arthrodesis, and osteotomy procedures, will be marketed and sold across the United States through RMR Ortho’s existing infrastructure, broadening the company’s reach into orthopaedic trauma, foot & ankle, and hand & wrist markets.
The partnership is positioned to strengthen Smith+Nebhew’s fixation portfolio. "This partnership with RMR Ortho strengthens Smith+Nebhew's fixation portfolio by adding a dynamic compression fixation solution that complements our existing technologies," said Scott Gunn, Vice President of U.S. Marketing, Trauma, Extremities, and Shoulder. He added, "The A'TOMIC Nitinol Fixation System expands our ability to participate in high‑frequency fracture and arthrodesis procedures while leveraging our established Extremities and Trauma sales channel to deepen surgeon engagement."
From RMR Ortho’s perspective, the deal expands access to the A'TOMIC system across key U.S. territories. "Partnering with Smith+Nebhew represents an important step forward for RMR Ortho as we continue to expand access to the A'TOMIC Nitinol Fixation System across key U.S. territories," said Joe Ritz, CEO of RMR Ortho. He noted, "Smith+Nebhew's established presence in orthopedic extremities and trauma, deep surgeon relationships, and commercial scale make them a strong partner as we work to deliver reliable, continuously compressive fixation solutions to surgeons, hospitals, and patients." RMR Group’s financial context shows a 22% year‑over‑year revenue decline in FY2025, but a 16.6% sequential revenue increase in Q1 2026, accompanied by significant gains in EBITDA and net income.
Smith+Nebhew’s 2024 sales totaled $5.8 billion, with its orthopaedics, sports medicine and ENT, and advanced wound management units driving growth. Adding the A'TOMIC system to its distribution network introduces a high‑margin specialty device that can enhance revenue streams and reinforce the company’s position in the orthopaedic fixation market.
The orthopaedic fixation market is driven by an aging population and rising sports‑related injuries. A'TOMIC’s nitinol alloy provides continuous compression and shape‑memory properties that differentiate it from conventional titanium systems, offering surgeons a reliable solution for complex fracture and fusion procedures. While the fact‑check does not list direct competitors, the technology’s unique material advantages are highlighted as a key selling point.
Financial terms of the agreement were not disclosed.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.